Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis - PubMed
7 hours ago
- #Immunoglobulin Therapy
- #Myasthenic Crisis
- #Efgartigimod
- Efgartigimod showed comparable remission rates (90.48%) to intravenous immunoglobulin (IVIg) (94.12%) for impending myasthenic crisis (IMC), with no significant difference (P=1.000).
- The median time to remission was significantly shorter with efgartigimod (8 days) compared to IVIg (12 days) (P=0.009), indicating a faster onset of action.
- Both treatments had low rates of progression to myasthenic crisis (efgartigimod: 4.76%, IVIg: 5.88%) and no treatment-emergent adverse events were reported, demonstrating similar safety profiles.
- The study was a single-center, randomized, open-label, prospective comparative cohort study involving 38 AChR-Ab+ patients with IMC, defined by specific clinical criteria such as MGFA grade IVb or QMG subscores.
- Secondary outcomes included improvements in QMG total, bulbar, and respiratory subscores, and MG-ADL scores from baseline to remission, supporting the efficacy of both treatments.